COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising
infection rates, patient groups characterized by an enhanced infection risk will be …

Background The COVID-19 pandemic has claimed the lives of nearly 2 million people
worldwide. 1 Following rapid sequencing of SARS-CoV-2, pharmaceutical companies and …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Background The effects that therapies for inflammatory bowel disease (IBD) have on
immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we …

Recent data suggest that inflammatory bowel disease (IBD) patients do not receive
preventive services at the same rate as general medical patients. Patients with IBD often …

SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide
the best opportunity for controlling transmission and protecting populations. Despite the …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

This ECCO topical review of the European Crohn's and Colitis Organisation [ECCO] focuses
on the epidemiology, pathophysiology, diagnosis, management and outcome of the two …

Background: Patients with immune-mediated diseases on immunosuppressive therapies
have more infectious episodes than healthy individuals, yet vaccination practices by …

Background & Aims In women with inflammatory bowel diseases (IBDs), exposure to
immunomodulator or biologic therapy has not been associated with adverse events during …